You are here

A Phase I/IIa Clinical Trial in Duchenne Muscular Dystrophy Using Systemically Delivered Morpholino Antisense Oligomer to Skip Exon 53 (SKIP-NMD)

Authors: 
No Authors Listed
Citation: 
Human Gene Therapy Clinical Development. June 2015, 26(2): 92-95. doi:10.1089/humc.2015.2528
Epub: 
Not Epub
Link to Publication: 
http://online.liebertpub.com/doi/abs/10.1089/humc.2015.2528
Organism or Cell Type: 
cell culture, tox models, humans